Obsessive-Compulsive Disorder
For OCD that has not responded adequately to SSRIs and exposure-and-response prevention therapy.
BrainsWay was the first device manufacturer to receive FDA clearance for any TMS treatment of OCD, in August 2018. The H7 coil — different in geometry from the depression-focused H1 — engages the medial prefrontal cortex and anterior cingulate, the cortical entry points to the cortico-striato-thalamo-cortical loop implicated in OCD.
OCD-targeted Deep TMS is typically delivered with brief individualized symptom provocation immediately before stimulation, to engage the relevant circuit before the magnetic pulses arrive.
FDA status
FDA-cleared (BrainsWay H7, 2018 — first TMS system cleared for OCD)
Standard protocol at IPMG TMS
5 sessions/week × 6 weeks · H7, individualized provocation, deep iTBS or HF
- 38% response vs 11% shamPivotal multisite RCT establishing FDA clearance.Carmi et al., Am J Psychiatry 2019
- 65% response · 33% remission (real-world)Accelerated H7 protocol, 378 patients, 15 sessions.Mudunuru et al., Cureus 2025
- 73% first response · 52% sustained at 1 month219 OCD patients across 22 H7 sites; YBOCS primary outcome.Roth et al., 2021
Who this is for.
- Adults with OCD inadequately responsive to SSRI ± ERP/CBT
- Patients seeking an option beyond medication and therapy
- Patients who can tolerate brief, individualized symptom provocation
Eligibility is finalized at consultation. We screen carefully for contraindications — see the Safety page.
Talk with the IPMG TMS team.
A consultation is the right next step. We will review your prior treatments, confirm whether you meet the FDA-cleared criteria for this indication, and walk you through what your insurance covers.